Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
76
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Acrivon Therapeutics Inc market cap is $49.35M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Acrivon Therapeutics Inc 52 week high is $3.56 as of November 21, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Acrivon Therapeutics Inc 52 week low is $0.9709 as of November 21, 2026.
Acrivon Therapeutics Inc stock price today is $1.15.
Acrivon Therapeutics Inc stock price yesterday was $1.40.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Acrivon Therapeutics Inc's P/E ratio is -0.63.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Acrivon Therapeutics Inc P/B ratio is 0.6972.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Acrivon Therapeutics Inc 50-day moving average is $1.76.